CD19 and cancer: Lymphodepletion with Cyclophosphamide (CP) and Fludarabine (FLU) has become an integral part of CAR-T therapies as it led to remarkable benefits across trials in both types of cancers, allowing for achievement of 72% overall response rate (ORR) and 50% complete remission (CR) in relapsed refractory Non-Hodgkin Lymphomas (NHL) treated with CD19 targeted CAR-T therapies, with enhanced T cell expansion as well as reducing immune responses to therapy (145).